The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection

  • Lee, Na-Ri (Division of Hematology and Oncology, Department of Internal Medicine, Chonbuk National University Medical School) ;
  • Jang, Ji Won (Division of Hematology and Oncology, Department of Internal Medicine, Chonbuk National University Medical School) ;
  • Kim, Hee Sun (Department of Nursing, Wonkwang University School of Medicine) ;
  • Yhim, Ho-Young (Division of Hematology and Oncology, Department of Internal Medicine, Chonbuk National University Medical School)
  • Received : 2014.11.13
  • Accepted : 2015.02.22
  • Published : 2015.07.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-1164. https://doi.org/10.1038/sj.leu.2404207
  2. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003;78:1578-1579. https://doi.org/10.4065/78.12.1578
  3. Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003;21:3171-3173. https://doi.org/10.1200/JCO.2003.03.037
  4. Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P. Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med 2004;25:479-519. https://doi.org/10.1016/j.ccm.2004.05.006
  5. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-743. https://doi.org/10.1016/S0140-6736(09)61303-9

Cited by

  1. Immunotherapy for tuberculosis: future prospects vol.5, pp.None, 2016, https://doi.org/10.2147/itt.s81892
  2. Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database vol.73, pp.12, 2017, https://doi.org/10.1007/s00228-017-2320-5
  3. Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection vol.34, pp.4, 2015, https://doi.org/10.4274/tjh.2017.0155
  4. Imatinib-induced irreversible interstitial lung disease : A case report vol.98, pp.8, 2015, https://doi.org/10.1097/md.0000000000014402
  5. Update on the management of chronic myeloid leukemia: current best practice and future directions vol.7, pp.4, 2015, https://doi.org/10.1080/21678707.2019.1609939
  6. Effects of host‐directed therapies on the pathology of tuberculosis vol.250, pp.5, 2015, https://doi.org/10.1002/path.5407
  7. Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia vol.27, pp.7, 2015, https://doi.org/10.1177/1078155220984239